NASDAQ: INDP
Indaptus Therapeutics Inc Stock Ownership - Who owns Indaptus Therapeutics?

Insider buying vs selling

Have Indaptus Therapeutics Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Jeffrey A. MecklerCEO and Director2024-11-2542,553$1.18
$50.00kBuy
Jeffrey A. MecklerCEO and Director2024-08-0884,932$1.83
$155.00kBuy

1 of 1

INDP insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when INDP insiders and whales buy or sell their stock.

INDP Shareholders

What type of owners hold Indaptus Therapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Dexcel Pharma Technologies Ltd739.51%4,234,897$46.97MInsider
Michael James Newman238.95%1,368,356$15.18MInsider
Glen R. Anderson227.77%1,304,318$14.46MInsider
Vanguard Group Inc44.75%256,265$2.84MInstitution
Jeffrey A. Meckler35.42%202,859$2.25MInsider
John W. Kozarich26.50%151,761$1.68MInsider
Investment House LLC22.50%128,851$1.43MInstitution
Geode Capital Management LLC21.82%124,967$1.39MInstitution
Anthony J. Maddaluna9.35%53,570$594.09kInsider
Strategy Asset Managers LLC7.92%45,336$502.78kInstitution

1 of 3

INDP vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
INDP8.05%91.95%Net Buying
PRTG2.77%0.00%
INAB48.10%51.90%Net BuyingNet Buying
CDIO25.06%74.94%Net Buying
AIM31.69%68.31%Net BuyingNet Buying

Indaptus Therapeutics Stock Ownership FAQ

Who owns Indaptus Therapeutics?

Indaptus Therapeutics (NASDAQ: INDP) is owned by 112.33% institutional shareholders, 1,283.58% Indaptus Therapeutics insiders, and 0.00% retail investors. Dexcel Pharma Technologies Ltd is the largest individual Indaptus Therapeutics shareholder, owning 4.23M shares representing 739.51% of the company. Dexcel Pharma Technologies Ltd's Indaptus Therapeutics shares are currently valued at $46.97M.

If you're new to stock investing, here's how to buy Indaptus Therapeutics stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.